Editorial: This isn't how the FDA should OK Alzheimer's drugs

LA Times | Opinion

Jun 8, 2021

Clinical trials looked bad for Biogen's pharmaceutical to treat Alzheimer's. So how did it win approval over the objections of an FDA advisory panel? |!| Los Angeles |!| Los Angele…